Edoxaban

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

Mar 27, 2017 → Oct 29, 2019

NCT ID

NCT02952599

About Edoxaban

Edoxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT02952599. Target conditions include Venous Thromboembolism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05804747	Pre-clinical	Completed	Feb 16, 2023	Jul 28, 2025	Atrial Fibrillation
NCT04747496	Pre-clinical	Completed	Feb 26, 2021	Nov 27, 2024	Non-valvular Atrial Fibrillation
NCT04594915	Pre-clinical	Completed	Aug 14, 2020	Jun 21, 2023	Atrial Fibrillation
NCT04519944	Pre-clinical	Completed	Jun 30, 2020	Jul 6, 2023	Non-valvular Atrial Fibrillation
NCT04171726	Phase 3	UNKNOWN	Aug 1, 2019	Sep 1, 2023	Aortic Valve Stenosis
NCT03840291	Approved	Completed	May 19, 2019	Aug 1, 2024	Atrial Fibrillation
NCT03247569	Pre-clinical	Completed	Oct 18, 2017	Feb 28, 2022	Atrial Fibrillation
NCT03247582	Pre-clinical	Completed	Aug 2, 2017	May 3, 2022	Atrial Fibrillation
NCT02952599	Pre-clinical	Completed	Mar 27, 2017	Oct 29, 2019	Venous Thromboembolism
NCT02951039	Pre-clinical	Completed	Feb 21, 2017	Oct 15, 2020	Atrial Fibrillation
NCT02964949	Pre-clinical	Completed	Jan 24, 2017	Oct 9, 2018	Atrial Fibrillation
NCT02943993	Pre-clinical	Completed	Apr 6, 2016	Dec 1, 2020	Venous Thromboembolism
NCT02944019	Pre-clinical	Completed	Aug 1, 2015	Apr 13, 2022	Atrial Fibrillation
NCT02448901	Pre-clinical	UNKNOWN	Apr 1, 2015	Mar 1, 2016	Heart Failure

Competing Products

20 competing products in Venous Thromboembolism

See all competitors

Product	Company	Stage	Hype Score
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)	Daiichi Sankyo	Phase 2	52
Edoxaban + Dalteparin + Low molecular weight heparin	Daiichi Sankyo	Phase 3	77
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Edoxaban + Standard of Care	Daiichi Sankyo	Phase 3	77
DU-176b + DU-176b + DU-176b + DU-176b + Placebo	Daiichi Sankyo	Phase 2	52
15mg DU-176b + 30mg DU-176b + Fondaparinux	Daiichi Sankyo	Phase 3	77
DU-176b (edoxaban) + Enoxaparin sodium 20mg	Daiichi Sankyo	Phase 3	77
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	77
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 3	77
YM150	Astellas Pharma	Phase 3	77
YM150	Astellas Pharma	Phase 3	77
YM150 + enoxaparin	Astellas Pharma	Phase 2/3	65
YM150 + Placebo + Enoxaparin	Astellas Pharma	Phase 2/3	65
YM150	Astellas Pharma	Phase 3	77
YM150	Astellas Pharma	Phase 3	77
YM150 + Placebo + Enoxaparin	Astellas Pharma	Phase 2/3	65
Dalteparin sodium + Dalteparin sodium/aspirin	Eisai	Pre-clinical	23
dalteparin injection	Eisai	Phase 3	77
ONO-7684 + ONO-7684 Placebo	Ono Pharmaceutical	Phase 1	33
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K Antagonist	Johnson & Johnson	Phase 2	52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved